Literature DB >> 15817641

Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.

Eric Wooltorton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817641      PMCID: PMC557066          DOI: 10.1503/cmaj.050373

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

Review 1.  Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.

Authors:  Darren M Ashcroft; Paul Dimmock; Ruth Garside; Ken Stein; Hywel C Williams
Journal:  BMJ       Date:  2005-02-24

2.  Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin.

Authors:  Y Niwa; T Terashima; H Sumi
Journal:  Br J Dermatol       Date:  2003-11       Impact factor: 9.302

  2 in total
  5 in total

1.  Questions and answers on immunization.

Authors:  Stéphane Paulus; Stuart Turvey
Journal:  Paediatr Child Health       Date:  2006-02       Impact factor: 2.253

2.  Topical calcineurin inhibitors in systemic lupus erythematosus.

Authors:  Christos E Lampropoulos; David P D'Cruz
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

3.  Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus.

Authors:  Michael Sticherling
Journal:  Biologics       Date:  2011-02-14

Review 4.  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs.

Authors:  Catharina M Lerche; Hans Christian Wulf
Journal:  Dermatol Reports       Date:  2010-09-14

5.  Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of atopic dermatitis in infants.

Authors:  Seul Ji Lee; Sung-il Woo; Soo Hyun Ahn; Dong Kyu Lim; Ji Yeon Hong; Jeong Hill Park; Johan Lim; Mi-kyeong Kim; Sung Won Kwon
Journal:  Sci Rep       Date:  2014-12-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.